Trial of NM-505 for treatment of type 2 diabetes

Trial Profile

Trial of NM-505 for treatment of type 2 diabetes

Phase of Trial: Phase II

Latest Information Update: 13 May 2015

At a glance

  • Drugs NM 505 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 May 2015 USFDA has responded positively to the company's pre-IND request to use the 505(b)(2) abbreviated pathway.
    • 09 Apr 2015 New trial record
    • 07 Apr 2015 According to a MicroBiome Therapeutics media release, this trial is planned in order to allow the company to seek FDA marketing approval via the expedited 505(b)(2) regulatory pathway.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top